Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)

ClinicalTrials.gov ID: NCT00620867

Public ClinicalTrials.gov record NCT00620867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee

Study identification

NCT ID
NCT00620867
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
393 participants

Conditions and interventions

Interventions

  • Ibuprofen Drug
  • celecoxib Drug
  • placebo Other

Drug · Other

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2002
Primary completion
Feb 28, 2003
Completion
Feb 28, 2003
Last update posted
Feb 20, 2021

2002 – 2003

United States locations

U.S. sites
33
U.S. states
19
U.S. cities
33
Facility City State ZIP Site status
Pfizer Investigational Site Anniston Alabama 36207
Pfizer Investigational Site Phoenix Arizona 85051
Pfizer Investigational Site Anaheim California 92804
Pfizer Investigational Site Long Beach California 90806
Pfizer Investigational Site Paramount California 90723
Pfizer Investigational Site San Diego California 92108
Pfizer Investigational Site DeLand Florida 32720
Pfizer Investigational Site Miami Florida 33186
Pfizer Investigational Site Naples Florida 34102
Pfizer Investigational Site Pembroke Pines Florida 33024
Pfizer Investigational Site St. Petersburg Florida 33710
Pfizer Investigational Site Chicago Illinois 60610
Pfizer Investigational Site Evansville Indiana 47712
Pfizer Investigational Site Las Vegas Nevada 89102
Pfizer Investigational Site Edison New Jersey 08817
Pfizer Investigational Site South Plainfield New Jersey 07080
Pfizer Investigational Site Albuquerque New Mexico 87109
Pfizer Investigational Site Brooklyn New York 11203
Pfizer Investigational Site New York New York 10022-1009
Pfizer Investigational Site Cincinnati Ohio 45242
Pfizer Investigational Site Columbus Ohio 43124
Pfizer Investigational Site Tulsa Oklahoma 74136
Pfizer Investigational Site Altoona Pennsylvania 16601
Pfizer Investigational Site Jenkintown Pennsylvania 19046
Pfizer Investigational Site Newtown Pennsylvania 18940
Pfizer Investigational Site Warwick Rhode Island 02886
Pfizer Investigational Site Charleston South Carolina 29407
Pfizer Investigational Site Greer South Carolina 29651
Pfizer Investigational Site Mt. Pleasant South Carolina 29464
Pfizer Investigational Site Johnson City Tennessee 37601
Pfizer Investigational Site Dallas Texas 75235
Pfizer Investigational Site Layton Utah 84041
Pfizer Investigational Site Danville Virginia 24541

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00620867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 20, 2021 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00620867 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →